Study Reveals High Markup of Cancer Drug Prices and Failure to Disclose Prices Publicly
The median price markup was as high as 633.6% for 1 drug.
The median price markup was as high as 633.6% for 1 drug.
The highest rate of non-concordant care was seen in patients with cervical cancer.
For all 5 metrics assessed, variation was largely due to unexplained reasons rather than patient factors.
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
About 1 in 20 patients had an invasive procedure due to a false-positive result.
The hospitalization rate was 49%, and 16% of patients died.
Treatment response, progression-free survival, and overall survival were all associated with patient-reported outcomes.
There was a significant increase in out-of-pocket costs for all 4 cancer types studied.
Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.